Patents Examined by Kevin E. Weddington
  • Methods of use for intermediate filament protein probes
    Patent number: 10690683
    Abstract: The present disclosure relates to compounds and methods for labeling and/or detecting proteins in vivo, and methods for probing mitochondrial structure and/or dynamics.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: June 23, 2020
    Assignee: University of Conneticut
    Inventors: Royce Mohan, Paola Bargagna-Mohan, Dennis L. Wright, Santosh Keshipeddy
  • Combination treatment for migraine and other pain
    Patent number: 10688102
    Abstract: Disclosed herein are methods of treating pain, such as migraine, comprising administering meloxicam and rizatriptan to a human being suffering from pain, such as migraine. For migraine, these methods may be particularly useful when the meloxicam and rizatriptan are administered while the human being is suffering from an acute attack of migraine pain or migraine aura. In some embodiments, the combination of meloxicam and rizatriptan may be administered in a manner that results in a Tmax of meloxicam of 3 hours or less.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: June 23, 2020
    Assignee: AXSOME THERAPEUTICS, INC.
    Inventor: Herriot Tabuteau
  • Methods for treating cancer using GRM8 inhibitors
    Patent number: 10683352
    Abstract: The present invention provides methods for treating cancer using mGluR8 inhibitors, such as mGluR8 inhibitory antibodies and small molecules. The invention also features compositions containing mGluR8 inhibitors, methods of diagnosing patients with mGluR8-associated cancer, and methods of predicting the response of cancer in a subject to treatment with mGluR8 inhibitors.
    Type: Grant
    Filed: January 30, 2019
    Date of Patent: June 16, 2020
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Julian Alexander Stanley
  • Method of treating metabolic disorders and depression with dopamine receptor agonists
    Patent number: 10675282
    Abstract: This invention relates to methods and formulations for treating metabolic disorders and depression. In some embodiments, the methods comprise administering a dopamine receptor agonist and an anti-depressant.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: June 9, 2020
    Assignee: VeroScience LLC
    Inventor: Anthony H. Cincotta
  • Targeted therapeutics
    Patent number: 10675360
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: October 25, 2018
    Date of Patent: June 9, 2020
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Drug combination with antitumor effects
    Patent number: 10675259
    Abstract: A drug combination with antitumor effects, contains styrene acid derivatives and antitumor medicaments with same or different specifications of unit preparations that can be simultaneously or separately administrated, as well as pharmaceutically acceptable carriers. The joint use of trans-styrene acid derivatives and antitumor drugs provides synergistic action, and the use of trans-styrene acid derivatives combined with a part of antitumor drugs can further exert the toxicity attenuation effects, showing a good clinical application prospect.
    Type: Grant
    Filed: September 1, 2016
    Date of Patent: June 9, 2020
    Assignee: DONGGUAN ANHAO PHARMACEUTICAL CO., LTD.
    Inventor: Zhiquan Yong
  • Uses of DPP IV inhibitors
    Patent number: 10668074
    Abstract: The specification describes the use of selected DPP IV inhibitors for the treatment of physiological functional disorders and for reducing the risk of the occurrence of such functional disorders in at-risk patient groups. In addition, the use of the above-mentioned DPP IV inhibitors in conjunction with other active substances is described, by means of which improved treatment outcomes can be achieved. These applications may be used to prepare corresponding medicaments.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: June 2, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Klaus Dugi, Frank Himmelsbach, Michael Mark
  • Amino compounds for treatment of medical disorders
    Patent number: 10660876
    Abstract: Compounds, methods of use, and processes for making inhibitors of complement Factor D comprising Formula I, or a pharmaceutically acceptable salt or composition thereof wherein R12 or R13 on the A group is an amino substituent (R32) are provided. The inhibitors of Factor D described herein reduce the excessive activation of complement.
    Type: Grant
    Filed: February 26, 2018
    Date of Patent: May 26, 2020
    Assignee: Achillion Pharmaceuticals, Inc.
    Inventors: Jason Allan Wiles, Avinash S. Phadke, Milind Deshpande, Atul Agarwal, Dawei Chen, Venkat Rao Gadhachanda, Akihiro Hashimoto, Godwin Pais, Qiuping Wang, Xiangzhu Wang
  • Alantolactone/isoalantolactone spiro aryl isoxazoline compounds
    Patent number: 10662201
    Abstract: A compound of chemical formula I: or chemical formula II: or a pharmaceutical acceptable salt thereof is disclosed. R1, R2, R3, and R4 are independently H, halogen, nitro, hydroxyl, cyano, benzyloxy, C1-C8 straight or branched alkyl, C1-C8 straight or branched haloalkyl, C1-C8 straight or branched alkoxy.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: May 26, 2020
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Chengyuan Liang, Xingke Ju, Lei Tian, Nan Qin, Juan Xia, Shaomeng Pei, Han Li, Yuzhi Liu
  • Single layer oral dose of neuro-attenuating ketamine
    Patent number: 10653629
    Abstract: The present invention is directed to oral neuro-attenuating ketamine (NAKET) tablet formulations, and methods of administration, which ensure the steady release of a therapeutically effective concentration of ketamine from an oral tablet without neurologically toxic spikes in ketamine concentration. In particular, the present invention provides single layer oral tablet formulation of NAKET. In a specific embodiment, the NAKET tablet formulation, and methods of administration provide steady administration of NAKET to a subject for 24 hours or greater, for example, up to 36 hours, after a single administration event.
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: May 19, 2020
    Assignee: Amorsa Therapeutics, Inc.
    Inventors: Alex Nivorozhkin, Nelson Landrau
  • Method of treatment
    Patent number: 10653665
    Abstract: Embodiments of the invention relate to the treatment of sleep disturbances in individuals with Smith-Magenis Syndrome (SMS).
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: May 19, 2020
    Assignee: Vanda Pharmaceuticals Inc.
    Inventors: Christian Lavedan, Mihael H. Polymeropoulos
  • Compositions and methods for treating chronic inflammation and inflammatory diseases
    Patent number: 10653778
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: November 30, 2018
    Date of Patent: May 19, 2020
    Assignee: Infirst Healthcare Limited
    Inventors: Robin M. Bannister, John Brew, Wilson Caparros-Wanderely, Suzanne J. Dilly, Olga Pleguezeulos Mateo, Gregory A. Stoloff
  • Methods of reducing hair loss and/or facilitating hair growth and/or regrowth
    Patent number: 10646429
    Abstract: The present disclosure relates to methods of retarding hair loss or facilitating hair growth and/or regrowth. More specifically, the present disclosure relates to methods of using the disclosed compositions to increase the rate of terminal hair growth and/or regrowth in a mammal.
    Type: Grant
    Filed: July 31, 2018
    Date of Patent: May 12, 2020
    Assignee: Johnson & Johnson Consumer Inc.
    Inventors: Longsheng Hu, Virginia Streusand Goldman, Josephine A. Minerva, Susan Wendling
  • Foaming oil cleanser composition
    Patent number: 10639270
    Abstract: A foaming oil cleanser composition and a method of preparing a foaming oil cleanser composition are provided. The foaming oil cleanser composition includes (a) a dialkyl sulfosuccinate, (b) Ricinus Communis Seed Oil, and (c) one or more oils. The foaming oil cleanser composition is essentially free of water and sulfate.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: May 5, 2020
    Assignee: L'OREAL
    Inventors: William Ronald Feuer, Miao Wang, Wivina Lijo
  • Heteroaromatic NMDA receptor modulators and uses thereof
    Patent number: 10626122
    Abstract: Disclosed herein, in part, are heteroaromatic compounds and methods of use in treating neuropsychiatric disorders, e.g., schizophrenia and major depressive disorder. Pharmaceutical compositions and methods of making heteroaromatic compounds are provided. The compounds are contemplated modulate the NMDA receptor.
    Type: Grant
    Filed: December 9, 2016
    Date of Patent: April 21, 2020
    Assignee: Cadent Therapeutics, Inc.
    Inventors: David R. Anderson, Robert A. Volkmann, Frank S. Menniti, Christopher Fanger
  • Methods of treating mixed dyslipidemia
    Patent number: 10624870
    Abstract: The present disclosure relates to, inter alia, methods of treating cardiovascular-related disease.
    Type: Grant
    Filed: February 25, 2019
    Date of Patent: April 21, 2020
    Assignee: AMARIN PHARMACEUTICALS IRELAND LIMITED
    Inventors: Ian Osterloh, Pierre Wicker, Rene Braeckman, Paresh Soni, Mehar Manku
  • Orally consumable cannabinoid composition including lecithin
    Patent number: 10617733
    Abstract: The present invention relates to a pharmaceutical composition comprising non-decarboxylated ?9 Tetrahydrocannabinol (THC), Cannabidiol (CBD), and at least one small molecule selected from Citric Acid, Ascorbic Acid, Citrus Essential Oil(s), Lecithin, one or more sugar(s), Resveratrol, and combinations thereof, wherein the composition exhibits enhanced therapeutic potency of THC and/or CBD. The present invention is further directed to methods of treating one or more disease(s) or disorder(s) modulated by the activation of the Cannabinoid CB1 and/or CB2 receptors, by administering a therapeutically effective amount of the composition of the present invention to a subject in need thereof.
    Type: Grant
    Filed: March 22, 2017
    Date of Patent: April 14, 2020
    Assignee: Rise Life Sciences Corp.
    Inventor: Brooks John Kelly
  • Agent for suppressing odors of polysulfide compounds
    Patent number: 10619027
    Abstract: Provided an agent for suppressing an odor of a polysulfide compound. This agent for suppressing an odor of a polysulfide compound comprises, as an active ingredient, at least one selected from the group consisting, butyl 2-methylbutanoate, ?-terpinene, dipentene, cis-4-heptenal, 1,4-cineol, trimethylhexyl aldehyde, and (+)-limonene oxide, wherein the polysulfide compound is represented by the following formula (I): R1—[S]n—R2 (I) (in the formula, R1 and R2 are the same or different, and each denote a linear-chain or branched-chain alkyl or alkenyl group having 1 to 6 carbon atoms, and n denotes an integer of 2 to 5).
    Type: Grant
    Filed: June 16, 2016
    Date of Patent: April 14, 2020
    Assignee: KAO CORPORATION
    Inventors: Keiichi Yoshikawa, Naoko Saito
  • 1-O-acetylbritannilatone spiro aryl isoxazoline compounds
    Patent number: 10618911
    Abstract: A compound of chemical formula I: or formula II: or a pharmaceutical acceptable salt thereof is disclosed. R1 is OH or OAc; X is C or N; and R2 is H, alkyl, alkoxy, benzyloxy, haloalkyl, OH, CN, NO2, or halogen, provided that when X is N, R2 is nil.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: April 14, 2020
    Assignee: SHAANXI UNIVERSITY OF SCIENCE AND TECHNOLOGY
    Inventors: Han Li, Yuzhi Liu, Nan Qin, Juan Xia, Shaomeng Pei, Chengyuan Liang, Lei Tian
  • Pharmaceutical composition and pharmaceutical dosage form comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide, process for their preparation, methods for treating and uses thereof
    Patent number: 10603292
    Abstract: The present invention relates to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide having the following chemical structure or a pharmaceutically acceptable salt thereof as active pharmaceutical ingredient, particularly to pharmaceutical compositions comprising (E)-4-(2-(aminomethyl)-3-fluoroallyloxy)-N-tert-butylbenzamide hydrochloride, to pharmaceutical dosage forms, to their preparation, their use and methods for therapeutic treatment.
    Type: Grant
    Filed: May 30, 2018
    Date of Patent: March 31, 2020
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Kenji Egusa, Takuma Katayama, Kazutoshi Yokoyama, Remko Alexander Bakker, Ngai Hang Victor Chong, Joerg Rippmann